AUS
NZ
UK
CA
USA
IND
Highlights
- Prescient (ASX:PTX) launches A$7M Share Purchase Plan
- Funds directed toward Phase 2 trials of targeted cancer therapy PTX-100
- PTX-100 holds Orphan Drug and Fast Track status from US FDA
Prescient Therapeutics (ASX:PTX) has initiated a Share Purchase Plan (SPP) aimed at raising up to A$7 million (before costs), as it moves forward with its clinical development goals. This funding round supports the continued advancement of PTX-100, the company’s lead immuno-oncology candidate targeting Cutaneous T-Cell Lymphoma (CTCL), a rare form of cancer.
The SPP offers eligible shareholders an opportunity to acquire new shares at A$0.04 per share — a 16.7% discount to the 15-day volume weighted average price (VWAP) and 9.1% below the closing price as of June 30, 2025. The offer is open to shareholders with an Australian or New Zealand address on record as of 7:00 pm (AEST) on June 30. The plan will close at 5:00 pm (AEST) on July 15, 2025.
Participants can apply for parcels ranging from A$5,000 to A$30,000, with no brokerage or transaction fees involved. Share allotment is scheduled for July 22, with quotation of the new shares expected on July 23. Depending on demand and regulatory parameters, scale-back provisions may apply.
Focus on Advancing PTX-100
Proceeds from the SPP will primarily fund the Phase 2 trials of PTX-100. This therapy targets a specific cancer pathway and has shown promising safety and efficacy data in earlier studies. The compound has already received Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration (FDA), highlighting its potential in addressing unmet clinical needs in rare cancers.
The Phase 2 trial is focused on Cutaneous T-Cell Lymphoma, a market estimated to be worth US$1.8 billion globally. Alongside clinical development, the raised capital will also help cover general working capital needs and costs associated with running the offer.
Prescient's strategic emphasis on precision oncology and immunotherapy continues to progress, and this funding initiative reflects the company’s commitment to delivering targeted cancer solutions with global market potential.
